Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
Charles Dolladille, Stéphane Éderhy, Stéphane Allouche, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000261-e000261
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4229-4361
Open Access | Times Cited: 1556
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal - Cardiovascular Imaging (2022) Vol. 23, Iss. 10, pp. e333-e465
Open Access | Times Cited: 210
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis
Charles Dolladille, Julia Akroun, Pierre‐Marie Morice, et al.
European Heart Journal (2021) Vol. 42, Iss. 48, pp. 4964-4977
Closed Access | Times Cited: 122
Immune Checkpoint Inhibitor Therapy in Oncology
Sean Tan, Daphne Day, Stephen J. Nicholls, et al.
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 579-597
Open Access | Times Cited: 94
Cardiovascular complications of immune checkpoint inhibitors for cancer
Franck Thuny, Jarushka Naidoo, Tomas G. Neilan
European Heart Journal (2022) Vol. 43, Iss. 42, pp. 4458-4468
Open Access | Times Cited: 74
Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis
Lorenz Lehmann, Markus Heckmann, Guillaume Bailly, et al.
Circulation (2023) Vol. 148, Iss. 6, pp. 473-486
Closed Access | Times Cited: 68
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure
Tamás G. Gergely, Zsófia D. Drobni, Marinos Kallikourdis, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 443-462
Closed Access | Times Cited: 15
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
Emanuel Raschi, Milo Gatti, Francesco Gelsomino, et al.
Targeted Oncology (2020) Vol. 15, Iss. 4, pp. 449-466
Open Access | Times Cited: 122
Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
Chen Chen, Bin Wu, Chenyu Zhang, et al.
International Immunopharmacology (2021) Vol. 95, pp. 107498-107498
Closed Access | Times Cited: 79
Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy
Yu. A. Vasyuk, G. E. Gendlin, Е. И. Емелина, et al.
Russian Journal of Cardiology (2021) Vol. 26, Iss. 9, pp. 4703-4703
Open Access | Times Cited: 62
Characterization of immune checkpoint inhibitor‐induced cardiotoxicity reveals interleukin‐17A as a driver of cardiac dysfunction after anti‐PD‐1 treatment
Tamás G. Gergely, Dániel Kucsera, Viktória É. Tóth, et al.
British Journal of Pharmacology (2022) Vol. 180, Iss. 6, pp. 740-761
Open Access | Times Cited: 39
Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin
Panagiotis Efentakis, Angeliki Choustoulaki, Grzegorz Kwiatkowski, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 13
Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
Tamás G. Gergely, Zsófia D. Drobni, Nabil V. Sayour, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 9
Cardiovascular toxicity of immune therapies for cancer
Nicolas L. Palaskas, Hyeon-Ju Ali, Efstratios Koutroumpakis, et al.
BMJ (2024), pp. e075859-e075859
Closed Access | Times Cited: 8
Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
Magdalena Zaborowska-Szmit, Maciej Krzakowski, Dariusz M. Kowalski, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 5, pp. 1268-1268
Open Access | Times Cited: 63
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Emanuel Raschi, Simone Rossi, Andrea De Giglio, et al.
Drug Safety (2023) Vol. 46, Iss. 9, pp. 819-833
Open Access | Times Cited: 18
A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients
Chin-Chin Ho, Shang-Liang Wu, Han‐Yi Tsai, et al.
Journal of the Chinese Medical Association (2023) Vol. 86, Iss. 5, pp. 499-505
Open Access | Times Cited: 16
Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge
Keila C. Ostos-Mendoza, Valeria Saraiba-Rabanales, Paola Gutierrez-Gallegos, et al.
The Journal of Cardiovascular Aging (2025) Vol. 5, Iss. 1
Open Access
Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
Xue Chen, Aimin Jiang, Rui Zhang, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 19
Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
Lu Gan, Demin Liu, Yanan Ma, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 19
A Rare Case of Overlapping Durvalumab-induced Myositis, Takotsubo-like Morphological Changes Caused by Myocarditis, and Myasthenia Gravis
Shoichiro Saito, Shigeto Hontsu, J Hiraoka, et al.
Internal Medicine (2024)
Open Access | Times Cited: 4
Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: multicenter study using natural language processing on Belgian hospital data
Danielle Delombaerde, Clara L. Oeste, Vincent Geldhof, et al.
ESMO Real World Data and Digital Oncology (2025) Vol. 7, pp. 100111-100111
Closed Access
Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review
Harun Muğlu, Erdem Sünger, Bahadır Köylü, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 302-302
Open Access
Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues
Valentina Bračun, Joseph Pierre Aboumsallem, Peter van der Meer, et al.
Current Oncology Reports (2020) Vol. 22, Iss. 7
Open Access | Times Cited: 30
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review
Alberto Servetto, Fabio Salomone, Fabrizio Di Costanzo, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 172, pp. 103649-103649
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top